avanos medical - AVNS

AVNS

Close Chg Chg %
25.00 0.06 0.24%

Closed Market

25.06

+0.06 (0.24%)

Volume: 823.33K

Last Updated:

Jun 5, 2026, 3:59 PM EDT

Company Overview: avanos medical - AVNS

AVNS Key Data

Open

$25.03

Day Range

25.00 - 25.10

52 Week Range

9.30 - 25.49

Market Cap

$1.17B

Shares Outstanding

46.83M

Public Float

45.10M

Beta

1.56

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.61

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.39M

 

AVNS Performance

1 Week
 
1.01%
 
1 Month
 
1.01%
 
3 Months
 
88.49%
 
1 Year
 
101.04%
 
5 Years
 
-36.00%
 

AVNS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About avanos medical - AVNS

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

AVNS At a Glance

Avanos Medical, Inc.
5405 Windward Parkway
Alpharetta, Georgia 30004-3894
Phone 1-844-428-2667 Revenue 701.20M
Industry Medical Specialties Net Income -72,900,000.00
Sector Health Technology 2025 Sales Growth 1.948%
Fiscal Year-end 12 / 2026 Employees 2,287
View SEC Filings

AVNS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.742
Price to Book Ratio 0.67
Price to Cash Flow Ratio 6.96
Enterprise Value to EBITDA 10.356
Enterprise Value to Sales 0.798
Total Debt to Enterprise Value 0.231

AVNS Efficiency

Revenue/Employee 306,602.536
Income Per Employee -31,875.82
Receivables Turnover 6.755
Total Asset Turnover 0.629

AVNS Liquidity

Current Ratio 2.151
Quick Ratio 1.255
Cash Ratio 0.544

AVNS Profitability

Gross Margin 47.547
Operating Margin 2.153
Pretax Margin -9.441
Net Margin -10.396
Return on Assets -6.544
Return on Equity -9.075
Return on Total Capital -8.035
Return on Invested Capital -7.808

AVNS Capital Structure

Total Debt to Total Equity 16.59
Total Debt to Total Capital 14.229
Total Debt to Total Assets 12.024
Long-Term Debt to Equity 14.225
Long-Term Debt to Total Capital 12.201
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Avanos Medical - AVNS

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
820.00M 673.30M 687.80M 701.20M
Sales Growth
+10.13% -17.89% +2.15% +1.95%
Cost of Goods Sold (COGS) incl D&A
370.00M 293.60M 306.50M 367.80M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
47.70M 43.50M 45.50M 38.90M
Depreciation
22.00M 19.20M 20.30M 19.70M
Amortization of Intangibles
25.70M 24.30M 25.20M 19.20M
COGS Growth
-3.24% -20.65% +4.39% +20.00%
Gross Income
450.00M 379.70M 381.30M 333.40M
Gross Income Growth
+24.24% -15.62% +0.42% -12.56%
Gross Profit Margin
+54.88% +56.39% +55.44% +47.55%
2022 2023 2024 2025 5-year trend
SG&A Expense
368.00M 314.70M 341.30M 318.30M
Research & Development
30.60M 27.20M 26.20M 22.60M
Other SG&A
337.40M 287.50M 315.10M 295.70M
SGA Growth
+15.69% -14.48% +8.45% -6.74%
Other Operating Expense
- - - -
-
Unusual Expense
4.50M 47.50M 440.10M 77.10M
EBIT after Unusual Expense
77.50M 17.50M (400.10M) (62.00M)
Non Operating Income/Expense
(2.30M) (10.40M) 9.00M 3.60M
Non-Operating Interest Income
1.20M 2.90M 5.10M 3.20M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
10.00M 15.00M 12.20M 7.80M
Interest Expense Growth
+203.03% +50.00% -18.67% -36.07%
Gross Interest Expense
10.00M 15.00M 12.20M 7.80M
Interest Capitalized
- - - -
-
Pretax Income
65.20M (7.90M) (403.30M) (66.20M)
Pretax Income Growth
+1,024.14% -112.12% -5,005.06% +83.59%
Pretax Margin
+7.95% -1.17% -58.64% -9.44%
Income Tax
14.70M 2.00M (17.00M) 6.70M
Income Tax - Current - Domestic
16.50M 6.10M 13.60M 9.90M
Income Tax - Current - Foreign
1.90M 4.00M 5.30M 4.60M
Income Tax - Deferred - Domestic
(3.30M) (6.80M) (35.00M) (8.00M)
Income Tax - Deferred - Foreign
(400.00K) (1.30M) (900.00K) 200.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
50.50M (9.90M) (386.30M) (72.90M)
Minority Interest Expense
- - - -
-
Net Income
50.50M (9.90M) (386.30M) (72.90M)
Net Income Growth
+871.15% -119.60% -3,802.02% +81.13%
Net Margin Growth
+6.16% -1.47% -56.16% -10.40%
Extraordinaries & Discontinued Operations
- - (51.90M) (5.80M)
-
Discontinued Operations
- - (51.90M) (5.80M)
-
Net Income After Extraordinaries
50.50M (61.80M) (392.10M) (72.90M)
Preferred Dividends
- - - -
-
Net Income Available to Common
50.50M (61.80M) (392.10M) (72.90M)
EPS (Basic)
1.0768 -1.3262 -8.5239 -1.5745
EPS (Basic) Growth
+896.11% -223.16% -542.73% +81.53%
Basic Shares Outstanding
46.90M 46.60M 46.00M 46.30M
EPS (Diluted)
1.0676 -1.3262 -8.5239 -1.5745
EPS (Diluted) Growth
+897.76% -224.22% -542.73% +81.53%
Diluted Shares Outstanding
47.30M 46.60M 46.00M 46.30M
EBITDA
129.70M 108.50M 85.50M 54.00M
EBITDA Growth
+57.40% -16.35% -21.20% -36.84%
EBITDA Margin
+15.82% +16.11% +12.43% +7.70%

Snapshot

Average Recommendation HOLD Average Target Price 14.00
Number of Ratings 1 Current Quarters Estimate 0.16
FY Report Date 06 / 2026 Current Year's Estimate 1.00
Last Quarter’s Earnings 0.22 Median PE on CY Estimate N/A
Year Ago Earnings 0.94 Next Fiscal Year Estimate 1.25
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate 0.16 0.33 1.00 1.25
High Estimates 0.16 0.33 1.00 1.25
Low Estimate 0.16 0.33 1.00 1.25
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Avanos Medical - AVNS

Date Name Shares Transaction Value
Apr 2, 2026 David C. Pacitti Chief Executive Officer 343,388 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2026 David C. Pacitti Chief Executive Officer 239,354 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2026 Scott M. Galovan SVP, Chief Financial Officer 139,824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2026 Scott M. Galovan SVP, Chief Financial Officer 96,212 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2026 Sigfrido Delgado SVP, Operations 60,005 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2026 Sigfrido Delgado SVP, Operations 59,434 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2026 John J. Hurley Principal Accounting Officer 11,381 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.29 per share 151,253.49

Avanos Medical in the News